Tsao David sold $2.0M of BLLN

Tsao David (Chief Technology Officer) sold 20,000 shares of BillionToOne, Inc. (BLLN) at an average of $102.27 ($98.74–$104.47, $2.05M total) across 11 trades on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tsao David
Published Jun 17, 2026, 9:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 9:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Neutral
medium confidence
Mentioned
$BLLN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNNeutralLow
01

Why it matters

The newest disclosed fact is the CTO’s open-market sale totaling ~$2.05M across 11 trades, executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor for follow-on insider activity, but the 10b5-1 designation suggests limited incremental information content.

03

What to watch

The filing shows remaining holdings (1,000 shares after sale) and a multi-tranche execution window; traders may overreact to the headline dollar amount without considering the plan’s mechanics.

Relevance 5/10Novelty 6/10Timing: Filed June 17; transactions executed June 15.

Background

This is an SEC Form 4 insider transaction disclosure for BillionToOne, Inc. (BLLN).

Company-level read

Ticker impact

$BLLNNeutralMedium confidence
Context

BillionToOne CTO Tsao David sold about $2.05M of BLLN shares in an open-market sale under a pre-arranged 10b5-1 plan on June 15.

Expected impact

Likely limited near-term impact; any reaction should be small unless accompanied by other company-specific catalysts.

Evidence & confidence

The filing is a primary-source Form 4 showing a sizable sale, yet it explicitly references a pre-arranged 10b5-1 plan, which typically dampens inference about new information.

Market effects

No clear sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Because the sale was executed under a pre-arranged 10b5-1 plan, it may reflect routine liquidity/compensation rather than a change in fundamentals.

Key entities

  • BillionToOne, Inc.

    Subject of the insider transaction disclosure; CTO sold shares totaling ~$2.05M under a 10b5-1 plan.

  • Tsao David

    Chief Technology Officer; reported open-market sale of BLLN shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.